A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT00922883, this PHASE2 trial focuses on Anemia, Aplastic and Anemia, Hypoplastic and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 14 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2020 — Nov 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Apr 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
For direct contact, visit the study record on ClinicalTrials.gov .